November 16, 2017 / 8:49 PM / a year ago

U.S. FDA expands approval for Pfizer cancer drug Sutent

Nov 16 (Reuters) - The U.S. Food and Drug Administration on Thursday approved the use of Pfizer Inc's cancer drug Sutent to help prevent kidney cancer from returning following surgical removal of a kidney.

Sutent was approved in 2006 for patients with gastrointestinal stromal tumors and advanced kidney cancer. It is also approved for patients with a certain type of pancreatic cancer.

The expanded approval allows Pfizer to market the drug for patients who have already had surgery to remove a kidney to reduce the risk of the cancer returning. It is the first treatment to be used in this setting.

A clinical trial showed that after five years, 59.3 percent of patients treated with Sutent had not had a recurrence of cancer or death compared with 51.3 percent of patients taking a placebo. (Reporting by Toni Clarke in Washington; Editing by Susan Thomas)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below